Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer

Benjamin R. Kipp, Mihaela Tanasescu, Terry A. Else, Sandra C. Bryant, Robert Jeffrey Karnes, Thomas J. Sebo, Kevin C. Halling

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Fluorescence in situ hybridization (FISH) testing is used to detect bladder cancer in urine specimens. The purpose of this study was to determine whether there are associations between the percentage of chromosomally abnormal cells by FISH and time to bladder cancer recurrence and progression to metastasis. Clinical records were searched to identify patients with urine FISH results, history of non-invasive bladder cancer, and at least one follow-up pathological diagnosis. Covariates analyzed included age, gender, smoking status, treatment after FISH, cystoscopy result, and prior stage of bladder cancer. The percentage of abnormal cells (hazard ratio [HR] 1.03, 95% CI 1.02-1.03; P < 0.001), age (HR 1.02, 95% CI 1.00-1.03; P = 0.033), male gender (HR 0.60, 95% CI 0.41-0.87; P < 0.001), treatment (HR 0.37, 95% CI 0.25-0.55; P < 0.001), and history of TIS/T1-stage tumors (HR 1.66, 95% CI 1.23-2.24; P = 0.001) were significantly associated with time to cancer recurrence. Time to invasive cancer was significantly associated with the percentage of abnormal cells (HR 1.02, 95% CI 1.01, 1.03; P < 0.001), history of TIS/T1 tumor (HR 3.73, 95% CI 1.88, 7.38; P = 0.001), and treatment (HR 0.33, 95% CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer.

Original languageEnglish (US)
Pages (from-to)148-154
Number of pages7
JournalJournal of Molecular Diagnostics
Volume11
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Aptitude
Fluorescence In Situ Hybridization
Urinary Bladder Neoplasms
Recurrence
Muscles
Neoplasms
Urine
Cystoscopy
Therapeutics
Smoking
Neoplasm Metastasis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. / Kipp, Benjamin R.; Tanasescu, Mihaela; Else, Terry A.; Bryant, Sandra C.; Karnes, Robert Jeffrey; Sebo, Thomas J.; Halling, Kevin C.

In: Journal of Molecular Diagnostics, Vol. 11, No. 2, 03.2009, p. 148-154.

Research output: Contribution to journalArticle

Kipp, Benjamin R. ; Tanasescu, Mihaela ; Else, Terry A. ; Bryant, Sandra C. ; Karnes, Robert Jeffrey ; Sebo, Thomas J. ; Halling, Kevin C. / Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. In: Journal of Molecular Diagnostics. 2009 ; Vol. 11, No. 2. pp. 148-154.
@article{3acd760a033447b2a8a61d057841b681,
title = "Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer",
abstract = "Fluorescence in situ hybridization (FISH) testing is used to detect bladder cancer in urine specimens. The purpose of this study was to determine whether there are associations between the percentage of chromosomally abnormal cells by FISH and time to bladder cancer recurrence and progression to metastasis. Clinical records were searched to identify patients with urine FISH results, history of non-invasive bladder cancer, and at least one follow-up pathological diagnosis. Covariates analyzed included age, gender, smoking status, treatment after FISH, cystoscopy result, and prior stage of bladder cancer. The percentage of abnormal cells (hazard ratio [HR] 1.03, 95{\%} CI 1.02-1.03; P < 0.001), age (HR 1.02, 95{\%} CI 1.00-1.03; P = 0.033), male gender (HR 0.60, 95{\%} CI 0.41-0.87; P < 0.001), treatment (HR 0.37, 95{\%} CI 0.25-0.55; P < 0.001), and history of TIS/T1-stage tumors (HR 1.66, 95{\%} CI 1.23-2.24; P = 0.001) were significantly associated with time to cancer recurrence. Time to invasive cancer was significantly associated with the percentage of abnormal cells (HR 1.02, 95{\%} CI 1.01, 1.03; P < 0.001), history of TIS/T1 tumor (HR 3.73, 95{\%} CI 1.88, 7.38; P = 0.001), and treatment (HR 0.33, 95{\%} CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer.",
author = "Kipp, {Benjamin R.} and Mihaela Tanasescu and Else, {Terry A.} and Bryant, {Sandra C.} and Karnes, {Robert Jeffrey} and Sebo, {Thomas J.} and Halling, {Kevin C.}",
year = "2009",
month = "3",
doi = "10.2353/jmoldx.2009.080096",
language = "English (US)",
volume = "11",
pages = "148--154",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

TY - JOUR

T1 - Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer

AU - Kipp, Benjamin R.

AU - Tanasescu, Mihaela

AU - Else, Terry A.

AU - Bryant, Sandra C.

AU - Karnes, Robert Jeffrey

AU - Sebo, Thomas J.

AU - Halling, Kevin C.

PY - 2009/3

Y1 - 2009/3

N2 - Fluorescence in situ hybridization (FISH) testing is used to detect bladder cancer in urine specimens. The purpose of this study was to determine whether there are associations between the percentage of chromosomally abnormal cells by FISH and time to bladder cancer recurrence and progression to metastasis. Clinical records were searched to identify patients with urine FISH results, history of non-invasive bladder cancer, and at least one follow-up pathological diagnosis. Covariates analyzed included age, gender, smoking status, treatment after FISH, cystoscopy result, and prior stage of bladder cancer. The percentage of abnormal cells (hazard ratio [HR] 1.03, 95% CI 1.02-1.03; P < 0.001), age (HR 1.02, 95% CI 1.00-1.03; P = 0.033), male gender (HR 0.60, 95% CI 0.41-0.87; P < 0.001), treatment (HR 0.37, 95% CI 0.25-0.55; P < 0.001), and history of TIS/T1-stage tumors (HR 1.66, 95% CI 1.23-2.24; P = 0.001) were significantly associated with time to cancer recurrence. Time to invasive cancer was significantly associated with the percentage of abnormal cells (HR 1.02, 95% CI 1.01, 1.03; P < 0.001), history of TIS/T1 tumor (HR 3.73, 95% CI 1.88, 7.38; P = 0.001), and treatment (HR 0.33, 95% CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer.

AB - Fluorescence in situ hybridization (FISH) testing is used to detect bladder cancer in urine specimens. The purpose of this study was to determine whether there are associations between the percentage of chromosomally abnormal cells by FISH and time to bladder cancer recurrence and progression to metastasis. Clinical records were searched to identify patients with urine FISH results, history of non-invasive bladder cancer, and at least one follow-up pathological diagnosis. Covariates analyzed included age, gender, smoking status, treatment after FISH, cystoscopy result, and prior stage of bladder cancer. The percentage of abnormal cells (hazard ratio [HR] 1.03, 95% CI 1.02-1.03; P < 0.001), age (HR 1.02, 95% CI 1.00-1.03; P = 0.033), male gender (HR 0.60, 95% CI 0.41-0.87; P < 0.001), treatment (HR 0.37, 95% CI 0.25-0.55; P < 0.001), and history of TIS/T1-stage tumors (HR 1.66, 95% CI 1.23-2.24; P = 0.001) were significantly associated with time to cancer recurrence. Time to invasive cancer was significantly associated with the percentage of abnormal cells (HR 1.02, 95% CI 1.01, 1.03; P < 0.001), history of TIS/T1 tumor (HR 3.73, 95% CI 1.88, 7.38; P = 0.001), and treatment (HR 0.33, 95% CI 0.13, 0.83; P = 0.019), suggesting that the percentage of abnormal cells independently predicts cancer recurrence and progression to invasive disease in patients with a history of non-invasive bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=64249144662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249144662&partnerID=8YFLogxK

U2 - 10.2353/jmoldx.2009.080096

DO - 10.2353/jmoldx.2009.080096

M3 - Article

C2 - 19179455

AN - SCOPUS:64249144662

VL - 11

SP - 148

EP - 154

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -